Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New job posting

<< Previous

Bullboard Posts

Next >>

Comment by stockman75on Jan 28, 2023 4:20am

117 Views

Post# 35251582

RE:RE:RE:RE:New job posting

Isn't that why we have an overpaid CEO from Pfizer?? I see where Goldman Sachs CEO is receiving a 29 percent pay cut for crappy results. As poorly as THTX has performed I think similar is in order for Thera.

palinc2000 wrote: If they have indeed idenfied less than strict adherence to stringent clinial and pre clinical methods and procedires and reporting etc that could be good news in the sense that they might be able to pivot and come up with corrective measures /

As I said before going from a strictky HIV focused company and overnight improvising to become a company involved in research in oncollogy with no experienced staff and no organisational structure to properly support these activities is bound to be a recipe for failure.....This new position is a demonstration of that flawed structure....
.

SPCEO1 wrote: That reads to me like an indictment of Christian. Perhaps on further review, the great preclinical work may have had some flaws? Or, it could be they found protocols were not being followed in the phase 1a and 1b leading to the pause due to weird results. There clearly is a big gap between the preclinical results and the still unknown phase 1a and 1b results, so I am sure they are trying to figure that out.
scarlet1967 wrote:
"Audit activities to ensure that Theratechnologies pre-clinical and clinical studies are conducted according to protocols and that any deviation is documented and assessed"
THTX isn't involved with any preclinical studies but Sort1!!